Loading clinical trials...
Loading clinical trials...
This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sunesis Pharmaceuticals
NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more
NCT06191978 · Acute Myeloid Leukemia
NCT06317649 · Acute Myeloid Leukemia
NCT06311227 · Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
NCT06299540 · Leukemia, Lymphocytic, Chronic, B-Cell
Mayo Clinic Hospital
Phoenix, Arizona
Mayo Clinic Scottsdale
Scottsdale, Arizona
Scripps Cancer Center
La Jolla, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions